

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

DECLARATION:

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT:

WHEREAS, we, the undersigned,

Alfredo C. CASTRO, resident of **14 Kelly Drive, Woburn, Massachusetts 01801, USA;**

Catherine Anne EVANS, resident of **83 Jaques Street, Somerville, Massachusetts 02145, USA;**

are inventors of the invention described and claimed in **"INDOLE AHR INHIBITORS AND USES THEREOF"** and hereby execute an International application therefor, having Application No. **PCT/US2018/028532**, filing date of **April 20, 2018**, and

are also aware of the following priority applications:

62/488,476, filing date of **April 21, 2017**;

62/592,542, filing date of **November 30, 2017**;

62/658,454, filing date of **April 16, 2018**;

WHEREAS, **KYN THERAPEUTICS** (hereinafter termed "Assignee"), having a place of business at **400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.


3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

Docket No.: 396661-001WO (159381)


4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

KYN THERAPEUTICS (“Assignee”)

By: 
Name: Mark Manfredi
Title: CEO and President
Date: _____

Docket No.: 396661-001WO (159381)

By:  Alfredo C. CASTRO Date: August 6, 2018 WITNESSES: Signature: _____ Signature: _____	By:  Catherine Anne EVANS Date: 6 Aug 2018 WITNESSES: Signature: _____ Signature: _____
--	--

**DECLARACIÓN COMBINADA (37 CFR § 1.63) Y CESIÓN (PROPÓSITO DUAL) PARA
LA SOLICITUD DE UTILIDAD O PATENTE DE DISEÑO QUE USA UNA HOJA DE
DATOS DE SOLICITUD**

DECLARACIÓN:

La solicitud dentro de la identificación fue hecha o autorizada para ser hecha por mí.

Creo que soy el inventor original o un inventor conjunto original de una invención reivindicada en la solicitud.

Por la presente reconozco que cualquier declaración falsa intencional hecha en esta declaración es punible bajo 18 U.S.C. § 1001 por multa o prisión de no más de cinco (5) años, o ambos.

CESIÓN:

CONSIDERANDO QUE, nosotros, los abajo firmantes,

Alfredo C. CASTRO, residente de **14 Kelly Drive, Woburn, Massachusetts 01801, EE.UU;**
Catherine Anne EVANS, residente de **83 Jaques Street, Somerville, Massachusetts 02145, EE.UU;**

somos inventores de la invención descrita y reivindicada en **"INHIBIDORES DEL RECEPTOR DE HIDROCARBUROS DE ARILO (AHR) DE INDOL Y USOS DE LOS MISMOS"** y por la presente ejecutar una solicitud Internacional para ello, que tiene el N° de Solicitud **PCT/US2018/028532**, fecha de presentación de **20 de abril de 2018**, y

también somos conscientes de la siguiente solicitud de prioridad:

62/488,476, fecha de presentación del **21 de abril de 2017**
62/592,542, fecha de presentación del **30 de noviembre de 2017**
62/658,454, fecha de presentación del **16 de abril de 2018**

CONSIDERANDO QUE, **KYN THERAPEUTICS** (en adelante denominado "Cesionario"), que tiene su domicilio comercial en **400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139, EE. UU.**, desea adquirir todo el derecho, título e interés en dicha solicitud y la invención descrita en ella, y en todas las realizaciones de la invención, concebidas, hechas o descubiertas por nosotros hasta ahora (todas colectivamente denominadas en lo sucesivo "dicha invención"), y en todas y cada una de las patentes, certificados de inventor y otras formas de protección (en lo sucesivo denominada "patentes") otorgada en los Estados Unidos y en países extranjeros.

AHORA, POR CONSIGUIENTE, en consideración de una contraprestación válida y susceptible de apreciación pecuniaria, cuyo recibo y suficiencia reconocemos haber recibido en su totalidad de dicho Cesionario:

1. Por la presente, vendemos, cedemos, transferimos y transmitimos a dicho cesionario, y/o confirmamos la cesión, transferencia o transporte previo a dicho cesionario, el completo derecho, título e interés (a) en y para dicha solicitud y dicha invención; (b) en y para todos los derechos a solicitar patentes extranjeras sobre dicha invención de conformidad con el Convenio Internacional para la Protección de la Propiedad Industrial o de otra manera; (c) en y para todas y cada una de las

Por: _____ <i>firma</i> _____ Alfredo C. Castro Fecha: 6 de agosto de 2018 TESTIGOS: Firma: Firma:	Por: _____ <i>firma</i> _____ Catherine Anne EVANS Fecha: 6 de agosto de 2018 TESTIGOS: Firma: Firma:
--	---